Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers
Zhi Liu, Peng Hou, Meiju Ji et al. · The Journal of Clinical Endocrinology & Metabolism · 2008
CONTEXT: Genetic alterations in receptor tyrosine kinases (RTKs) and phosphatidylinositol 3-kinase (PI3K)/Akt and MAPK pathways have not been fully defined in anaplastic and follicular thyroid cancers [anaplastic thyroid cancer (ATC), follicular thyroid cancer (FTC)]. OBJECTIVE: The objective of the study was to explore a wide-range genetic basis for the involvement of these pathways in ATC. DESIGN: We examined mutations and copy number gains of a large panel of genes in these pathways and corresponding phosphorylation of ERK (p-ERK) and Akt. RESULTS: We found frequent copy gains of RTK genes, including EGFR, PDGFRalpha and -beta, VEGFR1 and 2, KIT, and MET and in PIK3Ca, PIK3Cb, and PDK1 genes in the PI3K/Akt pathway. Mutations of Ras, PIK3Ca, PTEN, and BRAF genes and RET/PTC rearrangements were common, whereas mutations in PDK1, Akt1, Akt2, and RTK genes were uncommon in ATC. Overall, 46 of 48 ATC (95.8%) harbored at least one genetic alteration, and coexistence of two or more was seen in 37 of 48 ATC (77.1%). These genetic alterations were somewhat less common in FTC. Genetic alterations that could activate both the PI3K/Akt and MAPK pathways were found in 39 of 48 ATC (81.3%). RTK gene copy gains were preferentially associated with p-Akt, suggesting their dominant role in activating the PI3K/Akt pathway. The phosphorylation of Akt was far more common than p-ERK in FTC, and both were relatively common and often coexisted in ATC. CONCLUSIONS: Genetic alterations in the RTKs and PI3K/Akt and MAPK pathways are extremely prevalent in ATC and FTC, providing a strong genetic basis for an extensive role of these signaling pathways and the development of therapies targeting these pathways for ATC and FTC, particularly the former.
Cited by 390 works. doi:10.1210/jc.2008-0273
Authors
- Zhi Liu
- Peng Hou
- Meiju Ji
- Haixia Guan
- Kimberly Studeman
- Kirk Ernest Jensen
- Vasily V. Vasko
- Adel K. El‐Naggar
- Mingzhao Xing
References
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
- Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
- The discovery of receptor tyrosine kinases: targets for cancer therapy
- Targeting the mitogen-activated protein kinase cascade to treat cancer
- PI3K/Akt signalling pathway and cancer
- Mutations in a signalling pathway
- Epidermal growth factor receptor (EGFR) signaling in cancer
- The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
- Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors